Regenxbio: Cautiously Bullish After FDA Setbacks [Seeking Alpha]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Seeking Alpha
RGX-314 is being developed in partnership with AbbVie, targeting wet AMD and diabetic retinopathy. These are sizeable TAMs, which could pay off in the long run. RGX-202 also shows promising early Duchenne data and Phase 3 progress. However, we still need to see the trials' long-term efficacy and safety data. Unfortunately, RGNX's recent FDA setbacks in its MPS programs are now the main story. Their RGX-111 clinical hold and RGX-121 CRL add platform risks. But after the stock's considerable decline post-CRL, I feel RGNX is now again in a compelling valuation range. So I rate it a speculative “buy” at these levels. narvo vexar/iStock via Getty Images REGENXBIO Inc. ( RGNX ) is a biotech that develops AAV-based gene therapies for major diseases. RGNX's pipeline includes RGX-314 for wet age-related macular degeneration (wet AMD), with pivotal topline data planned for Q4 2026. Also, they have RGX-202 for Duchenne This article was written by Analyst's Disclosure: I/we have no
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of REGENXBIO Inc. Securities and Sets a Lead Plaintiff Deadline of April 14, 2026GlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNXPR Newswire
- REGENXBIO (NASDAQ:RGNX) was given a new $27.00 price target on by analysts at Robert W. Baird.MarketBeat
- REGENXBIO (NASDAQ:RGNX) was given a new $32.00 price target on by analysts at HC Wainwright.MarketBeat
- REGENXBIO (NASDAQ:RGNX) had its price target lowered by analysts at Morgan Stanley from $25.00 to $18.00. They now have an "overweight" rating on the stock.MarketBeat
RGNX
Earnings
- 11/6/25 - Beat
RGNX
Sec Filings
- 2/12/26 - Form 424B5
- 2/10/26 - Form 8-K
- 2/3/26 - Form 4
- RGNX's page on the SEC website